News & Updates

Adjuvant treatment with mRNA-4157 and pembrolizumab led to sustained improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) at approximately 3 years in individuals with resected high-risk melanoma as opposed to pembrolizumab alone, according to the updated results of the phase II KEYNOTE-942 trial presented at ASCO 2024.

A 15-day treatment course of nirmatrelvir-ritonavir appears to be safe but falls short of improving symptoms of postacute sequelae of SARS-CoV-2 infection (PASC) in a mostly vaccinated cohort, as shown in the results of the STOP-PASC trial.

The combination regimen comprising sotorasib and panitumumab demonstrates a trend towards an improvement in overall survival (OS) compared with investigator’s choice of therapy among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) who had progressed on systemic therapy, according to the OS analysis of the CodeBreak 300 trial presented at ASCO 2024.

Topical sildenafil cream appears to deliver promising outcomes for premenopausal women with sexual arousal disorder with or without concomitant decreased sexual desire, with increased arousal and reduced sexual distress, according to the results of an exploratory post hoc efficacy analysis of a phase IIb trial.

Outcomes of allogeneic hematopoietic cell transplant (alloHCT) do not differ in patients who underwent either one or two sets of busulfan therapeutic drug monitoring (TDM) sampling, reports a study.